

**§ 357.101**

- 357.150 Labeling of anthelmintic drug products.
- 357.152 Package inserts for anthelmintic drug products.
- 357.180 Professional labeling.

**Subpart C—Cholecystokinetic Drug Products**

- 357.201 Scope.
- 357.203 Definition.
- 357.210 Cholecystokinetic active ingredients.
- 357.250 Labeling of cholecystokinetic drug products.
- 357.280 Professional labeling.

**Subparts D–H [Reserved]**

**Subpart I—Deodorant Drug Products for Internal Use**

- 357.801 Scope.
- 357.803 Definitions.
- 357.810 Active ingredients for deodorant drug products for internal use.
- 357.850 Labeling of deodorant drug products for internal use.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

**Subpart A [Reserved]**

**Subpart B—Anthelmintic Drug Products**

SOURCE: 51 FR 27759, Aug. 1, 1986, unless otherwise noted.

**§ 357.101 Scope.**

(a) An over-the-counter anthelmintic drug product in a form suitable for oral administration is generally recognized as safe and effective and is not misbranded if it meets each condition in this subpart and each general condition established in § 330.1.

(b) References in this subpart to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

**§ 357.103 Definition.**

As used in this subpart:  
*Anthelmintic.* An agent that is destructive to worms.

**§ 357.110 Anthelmintic active ingredient.**

The active ingredient of the product is pyrantel pamoate when used within

**21 CFR Ch. I (4–1–07 Edition)**

the dosage limits established in § 357.150(d)(1).

**§ 357.150 Labeling of anthelmintic drug products.**

(a) *Statement of identity.* The labeling of the product contains the established name of the drug, if any, and identifies the product as a “pinworm treatment.”

(b) *Indication.* The labeling of the product states, under the heading “Indication,” the following: “For the treatment of pinworms.” Other truthful and nonmisleading statements, describing only the indications for use that have been established and listed in this paragraph (b), may also be used, as provided in § 330.1(c)(2), subject to the provisions of section 502 of the act relating to misbranding and the prohibition in section 301(d) of the act against the introduction or delivery for introduction into interstate commerce of unapproved new drugs in violation of section 505(a) of the act.

(c) *Warnings.* The labeling of the product contains the following warnings under the heading “Warnings”:

(1) “Abdominal cramps, nausea, vomiting, diarrhea, headache, or dizziness sometimes occur after taking this drug. If any of these conditions persist consult a doctor.”

(2) “If you are pregnant or have liver disease, do not take this product unless directed by a doctor.”

(d) *Directions.* The labeling of the product contains the following information under the heading “Directions”:

(1) Adults, children 12 years of age and over, and children 2 years to under 12 years of age: Oral dosage is a single dose of 5 milligrams of pyrantel base per pound, or 11 milligrams per kilogram, of body weight not to exceed 1 gram. Dosing information should be converted to easily understood directions for the consumer using the following dosage schedule:

Weight	Dosage (taken as a single dose) <sup>1</sup>
Less than 25 pounds or under 2 years old.	Do not use unless directed by a doctor.
25 to 37 pounds .....	125 milligrams.
38 to 62 pounds .....	250 milligrams.
63 to 87 pounds .....	375 milligrams.
88 to 112 pounds .....	500 milligrams.
113 to 137 pounds .....	625 milligrams.
138 to 162 pounds .....	750 milligrams.